Drugs / GT729
last change Dec 2025 re-read 3 minutes ago

GT729

Developed for
chronic graft versus host disease
Investigated by
Grit Biotechnology · Institute of Hematology & Blood Diseases Hospital, China

Trials 1

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT07253259 Dec 2025 → Nov 2027 expected chronic graft versus host disease Grit Biotechnology Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GT729 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07253259 ↗